

SafeStitch Medical, Inc.  
Form 4  
September 05, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Starling William N JR

(Last) (First) (Middle)  
3284 ALPINE ROAD  
(Street)

PORTOLA VALLEY, CA 94028  
(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
SafeStitch Medical, Inc. [SFES.OB]

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/03/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
--------------------------------------------	------------------------------------	--------------------------------------	----------------------------------------------------	--------------------------------	----------------------------------------------------	----------------------------------------------------------	---------------------------------------------------------------

Edgar Filing: SafeStitch Medical, Inc. - Form 4

	Derivative Security		Code	Disposed of (D) (Instr. 3, 4, and 5)			Date Exercisable	Expiration Date	Title	Amount or Number of Shares
				V	(A)	(D)				
Series B Preferred Stock	\$ 0.4 <sup>(1)</sup>	09/03/2013	P		866,234.4 <sup>(1)</sup>		<sup>(1)</sup>	<sup>(2)</sup>	Common Stock	8,662,34

### Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Starling William N JR 3284 ALPINE ROAD PORTOLA VALLEY, CA 94028		X		

### Signatures

/s/ William N. Starling, Jr.	09/03/2013
<small>**Signature of Reporting Person</small>	<small>Date</small>

### Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
 On September 3, 2013, SafeStitch Medical, Inc. (the "Issuer") sold and issued to Synergy Life Science Partners, L.P., in a privately negotiated transaction pursuant to a securities purchase agreement, an aggregate of 866,234.4 shares of the Issuer's Series B convertible preferred stock at a purchase price of \$4.00 per share. Upon the filing of an Amendment to the Issuer's Certificate of Incorporation with the State of Delaware, each share of the Issuer's Series B convertible preferred stock will automatically convert into ten (10) shares of the Issuer's common stock.
- (2) The Series B Preferred Stock has no expiration date.  
 The Reporting Person is a Manager of Synergy Venture Partners, LLC which serves as the sole General Partner of Synergy Life Science Partners, LP ("Synergy"). As such, the Reporting Person shares voting and investment control over the securities owned by Synergy, and may be deemed to own beneficially the securities held by Synergy. The Reporting Person disclaims beneficial ownership of the shares held by Synergy except to the extent of this proportionate pecuniary interest therein.
- (3)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.